Demonstrating the stability of albinterferon alfa-2b in the presence of silicone oil

Journal of Pharmaceutical Sciences

Volumn 100, Issue 12, 2011, Pages 5100-5114

  Auge, Kristin B ^a   Blake Haskins, Angela W ^a   Devine, Sean ^a   Rizvi, Sophia ^a,b   Li, Yi Ming ^a,c   Hesselberg, Mark ^a   Orvisky, Eduard ^a   Affleck, Richard P ^a   Spitznagel, Thomas M ^a   Perkins, Melissa D ^a  

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c MEDIMMUNE   (United States)

Author keywords

Analytical biochemistry; Analytical ultracentrifugation; Circular dichroism; Freeze drying lyophilization; FTIR; Protein aggregation; Protein delivery; Protein formulation; Protein structure; Stability

Indexed keywords

ALBINTERFERON ALPHA2B; ALBUMIN; PLACEBO; SILICONE OIL;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CAPSULE FILLING; CIRCULAR DICHROISM; DRUG FORMULATION; DRUG STABILITY; DRUG STRUCTURE; FREEZE DRYING; INFRARED SPECTROSCOPY; NONHUMAN; PARTICULATE MATTER; PROTEIN AGGREGATION; PROTEIN QUATERNARY STRUCTURE; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; TURBIDITY; ULTRACENTRIFUGATION;

EID: 80054886521     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22704     Document Type: Article

References (37)

1. Sharma B. 2007. Immunogenicity of therapeutic proteins. Part 2: Impact of container closures. Biotech Adv 25:318-324.
2. Riffkin C. 1968. Panel discussion: Siliconization of parenteral packaging components. I. Siliconization as applied to containers and closures. Bull Parenter Drug Assoc 22:66-69.
3. Elias W. 1968. Panel discussion: Siliconization of parenteral packaging components. II. Siliconization as applied to hypodermic needles. Bull Parenter Drug Assoc 22: 70-71.
4. Chantelau E. 1989. Silicone oil contamination of insulin. Diabet Med 6:278.
5. Bernstein RK. 1987. Clouding and deactivation of clear (regular) human insulin: Association with silicone oil from disposable syringes? Diabet Care 10:786-790.
6. Cleland J, Powell M, Shire S. 1993. The development of stable protein formulations: A close look at protein aggregation, deamidation, and oxidation. Crit Rev Ther Drug Carrier Syst 10:307-377.
7. Rosenburg A. 2006. Effects of protein aggregates: An immunologic perspective. AAPS J 8:501-507.
8. Bartzoka V, Brook M, McDermott M. 1998. Protein-silicone interactions: How compatible are the two species? Langmuir 14:1887-1891.
9. Jones L, Kaufmann A, Middaugh C. 2005. Silicone oil induced aggregation of proteins. J Pharm Sci 94:918-927.
10. Gabrielson J, Brader M, Pekar A, Mathis K, Winter G, Carpenter J, Randolph T. 2007. Quantitation of aggregate levels in a recombinant humanized monoclonal antibody formulation by size-exclusion chromatography, asymmetrical flow field fractionation, and sedimentation velocity. J Pharm Sci 96:268-279.
11. Thirumangalathu R, Krishnan S, Ricci M, Brems D, Randolph T, Carpenter J. 2009. Silicone-oil and agitation-induced aggregation of a monoclonal antibody in aqueous solution. J Pharm Sci 98:3167-3181.
12. Carpenter J, Randolph T, Jiskoot W, Crommelin D, Middaugh C, Winter G, Fan Y, Kirshner S, Verthelyi D, Kozlowski S, Clouse K, Swann P, Rosenburg A, Cherney B. 2009. Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J Pharm Sci 98:1201-1205.
13. Singh S, Afonina N, Awwad M, Bechtold-Peters D, Blue J, Chou D, Cromwell M, Krause H, Mahler H, Meyer B, Narhi L, Nesta D, Spitznagel T. 2010. An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics. J Pharm Sci 99:3302-3321.
14. Sharma D, Oma P, Pollo M, Sukumar M. 2010. Quantification and characterization of subvisible proteinaceous particles in opalescent mAB formulations using micro-flow imaging. J Pharm Sci 99:2628-2642.
15. Barnard J, Singh S, Randolph T, Carpenter J. 2011. Subvisible particle counting provides a sensitive method of detecting and quantifying aggregation of monoclonal antibody caused by freeze-thawing: insights into the roles of particles in the protein aggregation pathway. J Pharm Sci 100(2):492-503.
16. ICH Q6B test procedures and acceptance criteria for biotechnological/biological products-8/18/1999.
17. Eu B, Cairns A, Ding G, Cao X, Wen Z. 2011. Direct visualization of protein adsorption to primary containers by gold nanoparticles. J Pharm Sci 100:1663-1670.
18. Chou D, Krishnamurthy R, Randolph T, Carpenter J, Manning M. 2005. Effects of Tween 20® and Tween 80® on the stability of albutropin during agitation. J Pharm Sci 94:1368-1381.
19. Schuck P. 1998. Sedimentation analysis of non-interacting and self-associating solutes using numerical solutions to the Lamm equation modeling. Biophys J 75:1503-1512.
20. Schuck P. 2000. Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and Lamm equation modeling. Biophys J 78:1606-1621.
21. Schuck P, Rossmanith P. 2000. Determination of the sedimentation coefficient distribution by least squares boundary modeling. Biopolymers 54:328-341.
22. Schuck P, Perugini MA, Gonzales NR, Howlett GJ, Schubert D. 2002. Size-distribution analysis of proteins by analytical ultra-centrifugation: Strategies and application to model systems. Biophys J 82:1096-1111.
23. Lebowitz J, Lewis M, Schuck P. 2002. Modern analytical ultracentrifugation in protein science: A tutorial review. Protein Sci 11:2067-2079.
24. Gill S, Hippel P. 1989. Calculation of protein extinction coefficients from amino acid sequence data. Anal Biochem 182:319-326.
25. Laue TM, Shah BD, Ridgeway TM, Pelletier SL. 1992. Computer-aided interpretation of analytical sedimentation data for proteins. In Analytical ultracentrifugation in biochemistry and polymer science; Harding SE, Rowe AJ, Horton JC, eds. Cambridge, UK: Royal Society of Chemistry: pp 90-125.
26. Schmid F. Optical spectroscopy to characterize protein conformation and conformational changes. In: Protein structure: A practical approach. 2nd ed. New York: IRL Press;1997. p. 295
27. Sharma D, Oma P, Krishnan S. 2009. Silicone microdroplets in protein formulations: Detection and enumeration. Pharm Technol 33:74.
28. Carpenter J, Prestrelski S, Dong A. 1998. Application of infrared spectroscopy to development of stable lyophilized protein formulations. Eur J Pharm Biopharm 45:231-238.
29. Goormaghtigh E, Cabiaux V, Ruysschaert J. 1994. Determination of soluble and membrane protein structure by Fourier transform infrared spectroscopy III. Secondary structures. In: Subcellular biochemistry, Volume 23: Physiochemical methods in the study of biomembranes. New York: Plenum Press; pp 405-450.
30. Sugio S, Kashima A, Mochizuki S, Noda M, Kobayashi K. 1999. Crystal structure of human serum albumin at 2.5 Å resolution. Protein Eng 12:439-446.
31. 2b revealed by X-ray crystallography. Structure 4:1453-1463.
32. Peters T. 1985. Serum albumin. Adv Protein Chem 178:185-188.
33. Webb S, Cleland J, Carpenter J, Randolph T. 2002. A new mechanism for decreasing aggregation of recombinant human interferon-γ by a surfactant: Slowed dissolution of lyophilized formulations in a solution containing 0.03% polysorbate 20. J Pharm Sci 91:543-558.
34. Vrettos J, Affleck R, Guo J, Spitznagel T, Krishnamurthy R. 2006. Application of difference spectroscopy to biopharmaceutical formulation development. American Biotech Lab 24:24-27.
35. Ruiz L, Aroche K, Reyes N. 2006. Aggregation of recombinant human interferon alpha 2b in solution: Technical note. AAPS PharmSciTech 4(99):E1-5.
36. Ludwig B, Carpenter J, Hamel J, Randolph T. 2010. Protein adsorption and excipient effects on kinetic stability of silicone oil emulsions. J Pharm Sci 99(4):1721-1733.
37. Moore J, Patapoff T, Cromwell M. 1999. Kinetics and thermodynamics of dimer formation and dissociation for a recombinant humanized monoclonal antibody to vascular endothelial growth factor. Biochemistry 38:13960-13967.